Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor

BACKGROUND: Epidermal growth factor receptor (EGFR) alterations are associated with multiple cancers. Current EGFR‐directed therapies have led to increased efficacy but are associated with specific side effects. The antibody‐drug conjugate depatuxizumab mafodotin (depatux‐m) targets EGFR with a mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Goss, Glenwood D., Vokes, Everett E., Gordon, Michael S., Gandhi, Leena, Papadopoulos, Kyriakos P., Rasco, Drew W., Fischer, JuDee S., Chu, Katharine L., Ames, William W., Mittapalli, Rajendar K., Lee, Ho‐Jin, Zeng, Jiewei, Roberts‐Rapp, Lisa A., Loberg, Lise I., Ansell, Peter J., Reilly, Edward B., Ocampo, Christopher J., Holen, Kyle D., Tolcher, Anthony W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969257/
https://www.ncbi.nlm.nih.gov/pubmed/29533458
http://dx.doi.org/10.1002/cncr.31304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969257/
https://www.ncbi.nlm.nih.gov/pubmed/29533458
http://dx.doi.org/10.1002/cncr.31304

Ejemplares similares